Age-Based Comparison of Hematological Toxicity in Patients with Lung Cancer
- 1 November 2020
- journal article
- research article
- Published by S. Karger AG in Oncology
- Vol. 98 (11), 771-778
- https://doi.org/10.1159/000507864
Abstract
Introduction: Because of the increasing age of the general population, there is an increasing number of older patients with lung cancer. Cancer chemotherapy often causes severe hematological toxicity in older patients. Objective: This study aimed to explore the risk factors affecting the hematological toxicity of cytotoxic anticancer drugs in patients with lung cancer. Methods: Data were retrospectively collected from 194 patients with lung cancer at Niigata University Medical and Dental Hospital, Japan, between April 2011 and March 2016, when the patients underwent their first round of cytotoxic chemotherapy. The patients were divided into three groups on the basis of age: = 75 years. Physiological functions and laboratory data before treatment, as well as hematological adverse events following chemotherapy, were compared among the groups. Results: Patients aged >= 75 years were significantly more likely to experience grade 3 or 4 neutropenia, compared with patients aged = 75 years, male sex, and a performance status of >= 2 were independent factors for grade 3 or 4 neutropenia. Patients with 2 or 3 of these factors had a significantly higher frequency of neutropenia, compared with patients who had 0 or 1 of these factors. Conclusion: We found that age >= 75 years, male sex, and a performance status of >= 2 were independent risk factors for grade 3 or 4 neutropenia.This publication has 15 references indexed in Scilit:
- Validation of a Prediction Tool for Chemotherapy Toxicity in Older Adults With CancerJournal of Clinical Oncology, 2016
- Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non–Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 StudyJournal of Clinical Oncology, 2016
- International Society of Geriatric Oncology Consensus on Geriatric Assessment in Older Patients With CancerJournal of Clinical Oncology, 2014
- Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic reviewCritical Reviews in Oncology/Hematology, 2014
- Medical treatment of advanced non-small cell lung cancer in elderly patients: A review of the role of chemotherapy and targeted agentsJournal of Geriatric Oncology, 2013
- Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High‐Age Patients (CRASH) scoreCancer, 2011
- Predicting Chemotherapy Toxicity in Older Adults With Cancer: A Prospective Multicenter StudyJournal of Clinical Oncology, 2011
- Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trialThe Lancet, 2011
- Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patientsCancer, 2006
- Phase II Study of Carboplatin–Paclitaxel Combination Chemotherapy in Elderly Patients with Advanced Non-small Cell Lung CancerJapanese Journal of Clinical Oncology, 2005